Back

Insights from Comparison of the Renal and Skin Single Cell Transcriptomes in Lupus Nephritis

Der, E.; Suryawanshi, H.; Morozov, P.; Kustagi, M.; Goilav, B.; Ranabathou, S.; Izmirly, P.; Clancy, R.; Belmont, H. M.; Koenigsberg, M.; Mokrzycki, M.; Rominieki, H.; Graham, J.; Rocca, J.; Bornkamp, N.; Jordan, N.; Schulte, E.; Wu, M.; Pullman, J.; Slowikowski, K.; Raychaudhuri, S.; Guthridge, J.; James, J.; Acclerating Medicine Partnership (AMP), ; Buyon, J.; Tuschl, T.; Putterman, C.

2019-12-31 immunology
10.1101/382846 bioRxiv
Show abstract

Lupus nephritis (LN) occurs in up to 50% of patients with systemic lupus erythematosus (SLE), and is a major contributor to mortality and morbidity. LN presents as a highly heterogeneous disease both in histopathology and response to therapy. The molecular and cellular processes leading to renal damage and to the heterogeneity of the disease are not well understood. To elucidate the processes underpinning the heterogeneity of LN, we applied singlecell RNA-sequencing (scRNA-seq) to renal biopsies from LN patients. Skin biopsies were evaluated as a source of biomarkers for monitoring kidney disease. Type-I interferon (IFN) response signatures were identified in tubular cells and keratinocytes, differentiating LN patients from healthy controls. Non-responders associated with higher IFN signatures in both tissue compartments. Moreover, non-response was also associated with a fibrotic signature in the tubular cells. Receptor-ligand interaction analysis indicated that the fibrotic process is likely mediated by FGF receptors with the initiating signal originating from infiltrating leukocytes. Differential expression analysis of tubular cells between proliferative and membranous LN pointed to several fibrosis-relevant pathways, which may offer insight into their histological differences. In summary, scRNA-seq was applied to LN to deconstruct its heterogeneity and provide novel targets for personalized approaches to therapy.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Frontiers in Immunology
638 papers in training set
Top 0.2%
23.1%
2
JCI Insight
277 papers in training set
Top 0.2%
12.3%
3
Journal of Autoimmunity
10 papers in training set
Top 0.1%
10.1%
4
Annals of the Rheumatic Diseases
36 papers in training set
Top 0.1%
7.5%
50% of probability mass above
5
Arthritis & Rheumatology
36 papers in training set
Top 0.1%
6.5%
6
Scientific Reports
3612 papers in training set
Top 18%
5.3%
7
Clinical Immunology
21 papers in training set
Top 0.1%
5.0%
8
The Journal of Immunology
166 papers in training set
Top 1%
2.0%
9
PLOS ONE
5266 papers in training set
Top 47%
1.8%
10
Frontiers in Genetics
230 papers in training set
Top 2%
1.8%
11
Nature Communications
5641 papers in training set
Top 48%
1.4%
12
Disease Models & Mechanisms
20 papers in training set
Top 0.2%
1.2%
13
Nature Immunology
79 papers in training set
Top 2%
1.0%
14
Genome Medicine
183 papers in training set
Top 4%
1.0%
15
Kidney International
29 papers in training set
Top 0.4%
1.0%
16
Journal of Translational Medicine
57 papers in training set
Top 2%
0.9%
17
European Journal of Immunology
60 papers in training set
Top 1%
0.9%
18
eLife
5828 papers in training set
Top 67%
0.6%
19
Cell Death & Disease
21 papers in training set
Top 0.5%
0.6%
20
Human Molecular Genetics
141 papers in training set
Top 4%
0.5%
21
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 46%
0.5%
22
International Journal of Molecular Sciences
494 papers in training set
Top 19%
0.5%